- Home
- FFC vs ABUS Comparison
FFC vs ABUS Comparison
Compare FFC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- ABUS
- Stock Information
- Founded
- FFC 1983
- ABUS 2005
- Country
- FFC United States
- ABUS United States
- Employees
- FFC N/A
- ABUS 44
- Industry
- FFC Trusts Except Educational Religious and Charitable
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- FFC Finance
- ABUS Health Care
- Exchange
- FFC Nasdaq
- ABUS Nasdaq
- Market Cap
- FFC 725.6M
- ABUS 687.4M
- IPO Year
- FFC N/A
- ABUS N/A
- Fundamental
- Price
- FFC $15.52
- ABUS $3.23
- Analyst Decision
- FFC
- ABUS Strong Buy
- Analyst Count
- FFC 0
- ABUS 4
- Target Price
- FFC N/A
- ABUS $5.50
- AVG Volume (30 Days)
- FFC 164.1K
- ABUS 872.9K
- Earning Date
- FFC 01-01-0001
- ABUS 05-20-2025
- Dividend Yield
- FFC 6.79%
- ABUS N/A
- EPS Growth
- FFC N/A
- ABUS N/A
- EPS
- FFC N/A
- ABUS N/A
- Revenue
- FFC N/A
- ABUS $6,171,000.00
- Revenue This Year
- FFC N/A
- ABUS $14.57
- Revenue Next Year
- FFC N/A
- ABUS $15.84
- P/E Ratio
- FFC N/A
- ABUS N/A
- Revenue Growth
- FFC N/A
- ABUS N/A
- 52 Week Low
- FFC $11.90
- ABUS $2.63
- 52 Week High
- FFC $14.96
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- FFC 56.59
- ABUS 45.18
- Support Level
- FFC $15.36
- ABUS $3.11
- Resistance Level
- FFC $15.51
- ABUS $3.73
- Average True Range (ATR)
- FFC 0.12
- ABUS 0.16
- MACD
- FFC 0.07
- ABUS -0.01
- Stochastic Oscillator
- FFC 97.62
- ABUS 19.35
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.